← Retour à la listeCompanyRudaCure is actuellement developing the eye drop RCI001 centered around Professeur Donghyun Kim (Department of Ophthalmology, Gachon University). Dry eye disease — an uncomfortable condition for the eyes — is viewed as one type of trouble sensoriel. The treatment approach involves suppressing the abnormal signal transduction of Rac1, which is associated with the generation of reactive oxygen species and réponses inflammatoires, to treat sécheresse oculaire.
Some eye drops contain substances that stimulate pain nerves, causing discomfort upon instillation — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce élévation de la pression intraoculaire, a side effect that can lead to glaucoma.
RudaCure is also developing RCI002, a non narcotique traitement de la douleur. Since the American Pain Society filed for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of analgésiques narcotiques, the development of analgésique non narcotiques has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to pain signaling.
RudaCure is a growing company that is actively building partenariats with major entreprises pharmaceutiques. ← Retour à la liste
[Médecin-entrepreneur] Embrasser même la douleur — une histoire de passion
2022-02-21
Some eye drops contain substances that stimulate pain nerves, causing discomfort upon instillation — this is a well-known drawback. RCI001 does not stimulate nerves, so it does not cause pain when applied. It also does not produce élévation de la pression intraoculaire, a side effect that can lead to glaucoma.
RudaCure is also developing RCI002, a non narcotique traitement de la douleur. Since the American Pain Society filed for bankruptcy in 2019 after facing lawsuits for encouraging overprescription of analgésiques narcotiques, the development of analgésique non narcotiques has become a global priority. RCI002 reduces pain by inhibiting the function of TRPV1, a protein critical to pain signaling.
RudaCure is a growing company that is actively building partenariats with major entreprises pharmaceutiques.